29 results
8-K
EX-99.1
TERN
Terns Pharmaceuticals Inc
29 Apr 24
Regulation FD Disclosure
4:15pm
to a life-long chronic condition for most patients. Despite improvements in outcomes with active-site targeting TKIs, many patients do not achieve long-term disease
8-K
EX-1.1
TERN
Terns Pharmaceuticals Inc
15 May 23
Entry into a Material Definitive Agreement
4:44pm
equity incentive plans described in, the Registration Statement and the Prospectus), short-term debt or long-term debt of the Company or any of its
8-K
EX-1.1
nbp22637ut3a
23 Dec 22
Terns Announces Pricing of $75 Million Public Offering
4:10pm
424B5
o4x2djgpv4jp
21 Dec 22
Prospectus supplement for primary offering
4:22pm
424B5
uo7d7k sc0
20 Dec 22
Prospectus supplement for primary offering
7:21am
S-8
EX-99.1
jnqwdvqh5i kwynjyfcu
9 Nov 22
Registration of securities for employees
5:21pm
8-K
EX-1.1
1rdtx9d
16 Aug 22
Terns Announces $65 Million Oversubscribed Offering
5:18pm
424B5
j453ad
12 Aug 22
Prospectus supplement for primary offering
8:16am
DEF 14A
gb54hdy7d
29 Apr 22
Definitive proxy
4:22pm
S-3
EX-1.2
x16t i215
8 Mar 22
Shelf registration
4:34pm
10-K
91uvmlxrumqzlmrr
30 Mar 21
Annual report
5:21pm
S-8
EX-99.2
arzwyc2a1c0 cgew6j
12 Feb 21
Registration of securities for employees
5:06pm
424B4
08bevsn 6dq
8 Feb 21
Prospectus supplement with pricing info
4:01pm
S-1/A
u9p7gghj
1 Feb 21
IPO registration (amended)
7:05am